 AUSTIN, Texas, July 08, 2021 GLOBE NEWSWIRE -- Aspira Womens Health Inc. Nasdaq: AWH today announced its OVA1 risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Healths Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nations largest health care organizations. AIMs mission is to promote appropriate, safe, and affordable health care. As one of the nations leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments. 